Condition: Immune Thrombocytopenia · Treatment · Sponsor: Institute of Hematology & Blood Diseases Hospital, China
To evaluate the safety and efficacy of Obinutuzumab in the treatment of immune thrombocytopenia in patients who have not responded adequately or relapsed after first-line treatment.
This description comes directly from the study's public registry record.
Yunfei Chen, MD · +8618502220788 · chenyunfei@ihcams.ac.cn
Always discuss trial participation with your own doctor first.
| Chinese Academy of Medical Science and Blood Disease Hospital | Tianjin, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05995054